124 related articles for article (PubMed ID: 6678875)
1. Characterization of the pharmacokinetics of bisantrene (NSC-337766).
Kuhn JG; Ludden TM; Myers JW; Von Hoff DD
Invest New Drugs; 1983; 1(3):253-7. PubMed ID: 6678875
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride.
Lu K; Savaraj N; Yap BS; Feun LG; Umsawasdi T; Loo TL
Cancer Chemother Pharmacol; 1986; 16(2):156-9. PubMed ID: 3948302
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
4. Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride.
Powis G
J Chromatogr; 1981 Dec; 226(2):514-20. PubMed ID: 7320182
[No Abstract] [Full Text] [Related]
5. A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.
Weiss GR; Hersh M; Kuhn JG; Ludden TM; von Hoff DD; Kisner DL; Pirtle TE
Cancer Chemother Pharmacol; 1985; 15(2):144-8. PubMed ID: 4017163
[TBL] [Abstract][Full Text] [Related]
6. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
Yap BS; Yap HY; Blumenschein GR; Bedikian AY; Pocelinko R; Bodey GP
Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
[TBL] [Abstract][Full Text] [Related]
8. Bisantrene (NSC 337766) (CL 216,942) in advanced breast cancer. A cancer and leukemia group B study.
Forastiere AA; Perry MC; Hughes AK; Wood WC
Cancer Chemother Pharmacol; 1984; 13(3):226-9. PubMed ID: 6488443
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ametantrone acetate (NSC-287513).
Kuhn JG; Balmer CE; Ludden TM; Loesch DM; Von Hoff DD; Bender JF; Grillo-Lopez AJ
Cancer Chemother Pharmacol; 1987; 19(2):133-7. PubMed ID: 3568271
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
[TBL] [Abstract][Full Text] [Related]
11. Clinical kinetics of 1, 4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino ]-9, 10-anthracenedione.
Savaraj N; Lu K; Valdivieso M; Burgess M; Umsawasdi T; Benjamin RS; Loo TL
Clin Pharmacol Ther; 1982 Mar; 31(3):312-6. PubMed ID: 7060314
[TBL] [Abstract][Full Text] [Related]
12. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients.
Lam KS; Alberts DS; Peng YM; Brodar F; Matias B; Modiano M; Tuttle R; Sol Lucas V; Wargin W
Anticancer Drugs; 1992 Jun; 3(3):219-24. PubMed ID: 1525401
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of 9-10 anthracene-dicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl) hydrazone dihydrochloride (CL216,942; ADAH) in patients with advanced colorectal carcinoma.
Rubin J; Kvols LK; Moertel CG; Jones AR; Hahn RG; O'Connell MJ
Am J Clin Oncol; 1983 Aug; 6(4):477-9. PubMed ID: 6869319
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
Von Hoff DD; Myers JW; Kuhn J; Sandbach JF; Pocelinko R; Clark G; Coltman CA
Cancer Res; 1981 Aug; 41(8):3118-21. PubMed ID: 6265075
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas.
Miller TP; Jones SE; Alberts DS; Mackel C
Invest New Drugs; 1984; 2(1):75-7. PubMed ID: 6469502
[TBL] [Abstract][Full Text] [Related]
19. Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies.
Scher HI; Ahmed T; Yagoda A; Kyriazis AP; Watson RC
Cancer Invest; 1985; 3(2):123-7. PubMed ID: 3995377
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Malspeis L; Grever MR; Staubus AE; Young D
Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
